Cripto-1 As a Potential Target of Cancer Stem Cells for Immunotherapy

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Jun 2

PMID 34065315

Citations 8

Authors

Hiroko Ishii

Said M Afify

Ghmkin Hassan

David S Salomon

Masaharu Seno

Affiliations

Soon will be listed here.

Abstract

The immune system has been found to be suppressed in cancer patients. Cancer cells are extremely resistant to chemotherapeutic drugs, conventional immunotherapy, or cancer antigen vaccine therapy. Cancer immunotherapy, which is mainly based on immune checkpoint inhibitors, such as those for PD-1, PD-L1, and CTLA4, is an effective treatment method. However, no immunotherapeutic target has been found that retains validity in the face of tumor diversity. The transforming growth factor (TGF)-β cytokine family possesses broad biological activity and is involved in the induction and/or transdifferentiation of helper T cells, which are important in immunotherapy. Nodal is a member of the TGF-β family playing important roles in tissue stem cells and cancer stem cells (CSCs), interacting with the co-receptor Cripto-1, as well as with Activin type IB (Alk4) and Activin typeIIreceptors, and maintaining stemness and Notch and Wnt/β-catenin signaling in CSCs. In recent years, it has been reported that Cripto-1 could be a potential therapeutic target in CSCs. Here, we review the accumulated literature on the molecular mechanisms by which Cripto-1 functions in CSCs and discuss the potential of Cripto-1 as an immunotherapeutic target in CSCs.

Citing Articles

Induction, growth, drug resistance, and metastasis: A comprehensive summary of the relationship between STAT3 and gastric cancer.

Chen M, Wang T, Tian D, Hai C, Qiu Z Heliyon. 2024; 10(18):e37263.

PMID: 39309860 PMC: 11416542. DOI: 10.1016/j.heliyon.2024.e37263.

Impaired Osteogenesis in Human Induced Pluripotent Stem Cells with Acetaldehyde Dehydrogenase 2 Mutations.

Lim J, Han H, Jung S, Rim Y, Ju J Int J Stem Cells. 2024; 17(3):284-297.

PMID: 38604748 PMC: 11361852. DOI: 10.15283/ijsc23151.

Production in Bacteria and Characterization of Engineered Humanized Fab Fragment against the Nodal Protein.

Sivaccumar J, Iaccarino E, Oliver A, Cantile M, Olimpieri P, Leonardi A Pharmaceuticals (Basel). 2023; 16(8).

PMID: 37631045 PMC: 10459755. DOI: 10.3390/ph16081130.

CRISPR/Cas9 as a therapeutic tool for triple negative breast cancer: from bench to clinics.

Tiwari P, Ko T, Dubey R, Chouhan M, Tsai L, Singh H Front Mol Biosci. 2023; 10:1214489.

PMID: 37469704 PMC: 10352522. DOI: 10.3389/fmolb.2023.1214489.

CAR-Based Immunotherapy of Solid Tumours-A Survey of the Emerging Targets.

Maher J, Davies D Cancers (Basel). 2023; 15(4).

PMID: 36831514 PMC: 9953954. DOI: 10.3390/cancers15041171.

References

Desai A, Yan Y, Gerson S . Concise Reviews: Cancer Stem Cell Targeted Therapies: Toward Clinical Success. Stem Cells Transl Med. 2018; 8(1):75-81. PMC: 6312440. DOI: 10.1002/sctm.18-0123. View

Blankenstein T, Coulie P, Gilboa E, Jaffee E . The determinants of tumour immunogenicity. Nat Rev Cancer. 2012; 12(4):307-13. PMC: 3552609. DOI: 10.1038/nrc3246. View

Liu Q, Cui X, Yu X, Bian B, Qian F, Hu X . Cripto-1 acts as a functional marker of cancer stem-like cells and predicts prognosis of the patients in esophageal squamous cell carcinoma. Mol Cancer. 2017; 16(1):81. PMC: 5399850. DOI: 10.1186/s12943-017-0650-7. View

Mariathasan S, Turley S, Nickles D, Castiglioni A, Yuen K, Wang Y . TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018; 554(7693):544-548. PMC: 6028240. DOI: 10.1038/nature25501. View

Afify S, Seno M . Conversion of Stem Cells to Cancer Stem Cells: Undercurrent of Cancer Initiation. Cancers (Basel). 2019; 11(3). PMC: 6468812. DOI: 10.3390/cancers11030345. View

Gong W, Sun B, Sun H, Zhao X, Zhang D, Liu T . Nodal signaling activates the Smad2/3 pathway to regulate stem cell-like properties in breast cancer cells. Am J Cancer Res. 2017; 7(3):503-517. PMC: 5385639. View

Deng Z, Wu Y, Ma W, Zhang S, Zhang Y . Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM. BMC Immunol. 2015; 16:1. PMC: 4318439. DOI: 10.1186/s12865-014-0064-x. View

Foca G, Iaccarino E, Foca A, Sanguigno L, Untiveros G, Cuevas-Nunez M . Development of conformational antibodies targeting Cripto-1 with neutralizing effects in vitro. Biochimie. 2019; 158:246-256. DOI: 10.1016/j.biochi.2019.01.016. View

Oskarsson T, Batlle E, Massague J . Metastatic stem cells: sources, niches, and vital pathways. Cell Stem Cell. 2014; 14(3):306-21. PMC: 3998185. DOI: 10.1016/j.stem.2014.02.002. View

10.

Dillekas H, Demicheli R, Ardoino I, Jensen S, Biganzoli E, Straume O . The recurrence pattern following delayed breast reconstruction after mastectomy for breast cancer suggests a systemic effect of surgery on occult dormant micrometastases. Breast Cancer Res Treat. 2016; 158(1):169-178. PMC: 4937089. DOI: 10.1007/s10549-016-3857-1. View

11.

Ishiwata T . Cancer stem cells and epithelial-mesenchymal transition: Novel therapeutic targets for cancer. Pathol Int. 2016; 66(11):601-608. DOI: 10.1111/pin.12447. View

12.

Lo R, Leung C, Chan K, Ho D, Wong C, Lee T . Cripto-1 contributes to stemness in hepatocellular carcinoma by stabilizing Dishevelled-3 and activating Wnt/β-catenin pathway. Cell Death Differ. 2018; 25(8):1426-1441. PMC: 6113239. DOI: 10.1038/s41418-018-0059-x. View

13.

Adkins H, Bianco C, Schiffer S, Rayhorn P, Zafari M, Cheung A . Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo. J Clin Invest. 2003; 112(4):575-87. PMC: 171388. DOI: 10.1172/JCI17788. View

14.

Bianco C, Castro N, Baraty C, Rollman K, Held N, Rangel M . Regulation of human Cripto-1 expression by nuclear receptors and DNA promoter methylation in human embryonal and breast cancer cells. J Cell Physiol. 2012; 228(6):1174-88. PMC: 3573215. DOI: 10.1002/jcp.24271. View

15.

Okazaki T, Honjo T . PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol. 2007; 19(7):813-24. DOI: 10.1093/intimm/dxm057. View

16.

De Luca A, Lamura L, Strizzi L, Roma C, DAntonio A, Margaryan N . Expression and functional role of CRIPTO-1 in cutaneous melanoma. Br J Cancer. 2011; 105(7):1030-8. PMC: 3185940. DOI: 10.1038/bjc.2011.324. View

17.

Qi C, Liscia D, Normanno N, Merlo G, Johnson G, Gullick W . Expression of transforming growth factor alpha, amphiregulin and cripto-1 in human breast carcinomas. Br J Cancer. 1994; 69(5):903-10. PMC: 1968887. DOI: 10.1038/bjc.1994.174. View

18.

Bianco C, Normanno N, De Luca A, Maiello M, Wechselberger C, Sun Y . Detection and localization of Cripto-1 binding in mouse mammary epithelial cells and in the mouse mammary gland using an immunoglobulin-cripto-1 fusion protein. J Cell Physiol. 2002; 190(1):74-82. DOI: 10.1002/jcp.10037. View

19.

Sandomenico A, Ruvo M . Targeting Nodal and Cripto-1: Perspectives Inside Dual Potential Theranostic Cancer Biomarkers. Curr Med Chem. 2018; 26(11):1994-2050. DOI: 10.2174/0929867325666180912104707. View

20.

Budhu S, Schaer D, Li Y, Toledo-Crow R, Panageas K, Yang X . Blockade of surface-bound TGF-β on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment. Sci Signal. 2017; 10(494). PMC: 5851440. DOI: 10.1126/scisignal.aak9702. View